BTIG Maintains Buy on Xtant Medical Hldgs, Raises Price Target to $3
Benzinga Newsdesk 2 years ago
NewsPrice TargetAnalyst Ratings
BTIG analyst Ryan Zimmerman maintains Xtant Medical Hldgs (AMEX:XTNT) with a Buy and raises the price target from $2 to $3.
BTIG analyst Ryan Zimmerman maintains Xtant Medical Hldgs (AMEX:XTNT) with a Buy and raises the price target from $2 to $3.